(Alliance News) - MaxCyte Inc on Wednesday said it has signed a strategic platform licence with TG Therapeutics Inc to develop its autoimmune cell therapy.
The Rockville, Maryland-based provider of cell engineering platform technologies said it will receive annual licensing fees and program-related revenue under the agreement.
TG Therapeutics gains research, clinical and commercial rights to use MaxCyte's flow electroporation technology and Expert platform to support the development of azer-cel, a cell therapy programme to treat autoimmune diseases.
Chief Executive Officer Maher Masoud said: "By leveraging our commercially validated cell-engineering platform and optimized T cell manufacturing workflow, TG Therapeutics is advancing toward their phase 1 clinical trial for the application of azer-cel in progressive forms of MS... With our new partnership, we will continue to support the development of azer-cel to expand the application to autoimmune diseases."
Shares in MaxCyte were up 0.7% to 342.50 pence in London on Wednesday morning.
By Michael Hennessey, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2025 Alliance News Ltd. All Rights Reserved.
MaxCyte (MXCT)
